$30.36
0.20[0.66%]
At close: Apr 26
Latest News for Ipsen Stock (OTC:IPSEY)
Ipsen Stock (OTC: IPSEY)
Categories: All
Monday, April 22, 2024
Tuesday, April 02, 2024
Wednesday, March 27, 2024
Tuesday, February 13, 2024
- Ipsen's Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDABenzinga Newsdesk - Feb 13, 2024, 4:50PM
- BZ NOTE: Merrimack Pharmaceuticals, As Part Of Its Agreement With Ipsen For The Sale Of Its Oncology Assets Including ONIVYDE, Is Eligible To Receive Additional Payments With The Possibility Of Up To $450M Contingent Upon The Approval Of Potential New Indications For ONIVYDE In The U.S.Benzinga Newsdesk - Feb 13, 2024, 1:31PM
- FDA Approves Irinotecan Liposome For First-line Treatment Of Metastatic Pancreatic AdenocarcinomaBenzinga Newsdesk - Feb 13, 2024, 1:19PM
Thursday, December 07, 2023
- Ipsen Confirms FDA Grants Priority Review For New Drug Application For Elafibranor For The Treatment Of Rare Cholestatic Liver Disease, PBCCharles Gross - Dec 7, 2023, 5:17AM
- U.S. FDA Grants Priority Review For Ipsen's New Drug Application For Elafibranor For The Treatment Of Rare Cholestatic Liver Disease, PBCBenzinga Newsdesk - Dec 7, 2023, 1:45AM
Monday, August 21, 2023
- Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer PatientsVandana Singh - Aug 21, 2023, 2:57PM
- Exelixis And Ipsen Announce Results From Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib In Combination With Atezolizumab In Metastatic Castration-Resistant Prostate CancerBenzinga Newsdesk - Aug 21, 2023, 1:27AM
Friday, June 30, 2023
- Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-ClassVandana Singh - Jun 30, 2023, 2:51PM
- Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis PatientsVandana Singh - Jun 30, 2023, 2:03PM
- Ipsen And Genfit Announced Topline Data From The Pivotal ELATIVE Phase 3 Trial, Of Elafibrano For Primary Biliary Cholangitis; The Trial Met Its Primary Composite Endpoint, With 51% Of Patients Achieving Cholestasis Response Compared With 4% On PlaceboBenzinga Newsdesk - Jun 30, 2023, 6:18AM
Monday, May 22, 2023
Monday, January 09, 2023
Wednesday, December 14, 2022
Friday, December 09, 2022
Wednesday, November 09, 2022
- Why Merrimack Shares Are Surging Over 200% Today?Vandana Singh - Nov 9, 2022, 9:04AM
- Shares of Merrimack Pharmaceuticals Rise 100% Preamarket Following Ipsen Report that Onivyde Met Primary and Key Secondary Endpoint; Merrimack is Eligible for Up to $450M Milestone Payment for the Pancreatic Cancer TreatmentCharles Gross - Nov 9, 2022, 5:25AM
- Ipsen Announced Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma; Trial Met its Primary Endpoint and Key Secondary EndpointCharles Gross - Nov 9, 2022, 5:21AM
Tuesday, November 01, 2022
Sunday, October 02, 2022
Monday, September 19, 2022
Wednesday, August 03, 2022
Tuesday, June 28, 2022
Monday, June 27, 2022
- Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day SessionLisa Levin - Jun 27, 2022, 12:26PM
- The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas StudiesVandana Singh - Jun 27, 2022, 10:50AM
- Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read WhyVandana Singh - Jun 27, 2022, 6:45AM
- Ipsen to Acquire Epizyme for $1.45/Share in Cash, Plus a Contingent Value Right of $1.00/ShareCharles Gross - Jun 27, 2022, 5:15AM
Tuesday, May 03, 2022
Friday, March 25, 2022
Tuesday, March 15, 2022
Monday, January 24, 2022
Friday, December 17, 2021
- Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment HopefulVandana Singh - Dec 17, 2021, 6:25AM
- Ipsen and GENFIT Announced Exclusive Licensing Agreement for Elafibranor; GENFIT Receives €120M Upfront, Up to €360M in Milestone Payments Plus Royalties of up to 20%; Ipsen Becomes 8% Shareholder of GENFITCharles Gross - Dec 17, 2021, 4:54AM
Friday, August 13, 2021
Monday, August 02, 2021
- Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative DisordersVandana Singh - Aug 2, 2021, 7:24AM
- Exicure Shares Surge 43% Premarket; Exicure Announced Collaboration With IpsenTargeting Rare Neurodegenerative Disorders; Ipsen to Pay Exicure $20M UpfrontCharles Gross - Aug 2, 2021, 5:06AM
Thursday, July 15, 2021
Monday, June 28, 2021
- Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver CancerVandana Singh - Jun 28, 2021, 8:40AM
- Exelixis and Ipsen Announced Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver CancerCharles Gross - Jun 28, 2021, 5:41AM
Thursday, April 01, 2021
Friday, February 26, 2021
Wednesday, June 17, 2020
- The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA RevokedShanthi Rexaline - Jun 17, 2020, 7:30AM
- Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan as First-Line Combination Treatment for Metastatic Pancreatic CancerCharles Gross - Jun 17, 2020, 5:38AM